article thumbnail

Eli Lilly inks deal to acquire Nexus manufacturing plant in WI as Mounjaro and Zepbound shortages drag on

Fierce Pharma

As doctors and patients in the U.S. | As doctors and patients in the U.S. grapple with widening shortages of the popular diabetes therapy Mounjaro and its obesity counterpart Zepbound, the maker of the tirzepatide drugs, Eli Lilly, is forging ahead on its quest to expand capacity for its injectable medicines.

Doctors 256
article thumbnail

FDA turns down Outlook's ophthalmic version of Roche's Avastin over manufacturing, data shortfalls

Fierce Pharma

Even without an FDA approval, Roche’s cancer drug Avastin is widely used by doctors to treat certain eye diseases. Even without an FDA approval, Roche’s cancer drug Avastin is widely used by doctors to treat certain eye diseases.

FDA 290
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Marketing to Doctors and Physicians

Healthcare Success

Every time I run into someone who is faced with the daunting challenge of marketing to doctors or other healthcare professionals, I giggle empathetically and say, “I feel your pain.”. Get Your Doctors’ Attention Immediately. Doctors are notoriously hard to reach and persuade. Always offer specific solutions to specific problems.

Doctors 57
article thumbnail

Episode 15 – Patient Builder – A Win for Doctors/Clinics and A Win for Medical Device Companies Trying to Add Value

Medical Device Success

Bill and his team have a unique view of the medical device world in that they consult for practices, they act as a provider via ambulatory surgical centers and then they work with the medical device industry by helping industry and doctors work together to maximize technology integration and patient uptake via their Patient Builder tools.

Doctors 100
article thumbnail

Towards ‘smart’ vaccine development and manufacturing

European Pharmaceutical Review

However, the biopharma industries realised that traditional vaccine development and manufacturing techniques, which take around five to 10 years for initial development to large-scale distribution, 1 were inadequate to meet the growing demand for COVID-19 vaccines. Digital technologies for smart vaccine manufacturing.

article thumbnail

Simplify, standardise, digitalise to transform manufacturing

European Pharmaceutical Review

Our ambition is to build a modern, industry-leading manufacturing network, by bringing together talented people and cutting-edge processes, technologies and data to reliably deliver high quality, affordable and sustainable medicines and vaccines to patients. Standardise manufacturing .

article thumbnail

Monitoring pharmaceuticals in the environment

European Pharmaceutical Review

While pharmaceutical manufacturing’s overall contribution is small compared to patient use and inappropriate disposal of pharmaceuticals, inadequately managed manufacturing emissions can impact local environments and receiving waters.